Welcome to our dedicated page for Recursion Pharmaceuticals news (Ticker: RXRX), a resource for investors and traders seeking the latest updates and insights on Recursion Pharmaceuticals stock.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a clinical-stage TechBio company that regularly issues news and updates about its platform, pipeline and partnerships. As a biotechnology company focused on decoding biology to radically improve lives, Recursion generates announcements that span clinical trial readouts, business development milestones and technology advances related to its Recursion OS.
News for RXRX often highlights progress in clinical programs, such as the TUPELO Phase 1b/2 trial of REC-4881 in familial adenomatous polyposis (FAP), the ELUCIDATE Phase 1/2 trial of REC-617 in advanced solid tumors and ovarian cancer, and the DAHLIA Phase 1/2 study of REC-1245 in solid tumors. Company communications describe efficacy, safety, and design details for these studies, as well as plans for future data readouts and regulatory interactions.
Investors also see frequent updates on partnerships and collaborations. Recursion reports milestones from its long-term collaboration with Genentech and F. Hoffmann-La Roche Ltd, including acceptance of whole-genome phenotypic maps such as a microglia map, and from its multi-target collaboration with Sanofi in oncology and immunology. These items often include information about milestone payments and the scope of ongoing discovery work.
Additional RXRX news covers financial results and capital markets activity, such as quarterly earnings releases, cash runway commentary, and disclosures related to registration statements and share issuances connected to collaborations or acquisitions. The company also announces participation in healthcare and investor conferences, webinars on clinical data, and leadership changes, including CEO transition plans.
By following the RXRX news feed, readers can track how Recursion’s Recursion OS platform is being applied across its internal pipeline and partnered programs, as well as how business decisions, collaborations and governance developments may shape the company’s trajectory in the TechBio and biotechnology sectors.
Recursion (RXRX) and Exscientia have completed their business combination, with Exscientia becoming a wholly owned subsidiary of Recursion. The merged entity now features more than 10 clinical and preclinical programs, 10 advanced discovery programs, and over 10 partnered programs. The company has received $450M in upfront and milestone payments to date, with potential for over $20B in additional milestone payments. The combined platform integrates Exscientia's chemical design methods with Recursion's 60+ petabytes of proprietary data. The merged company will employ approximately 800 people, headquartered in Salt Lake City with offices across North America and Europe.
Recursion (RXRX) and Exscientia (EXAI) shareholders have approved their proposed business combination, with the transaction expected to close on November 20, 2024. The combined company will integrate Recursion's biological and chemical exploration capabilities with Exscientia's molecular design and automated chemistry synthesis expertise to enhance drug discovery processes. An update call is scheduled for November 20, 2024, at 7:30 a.m. ET. The final voting results will be disclosed in regulatory filings with the SEC.
Recursion (NASDAQ: RXRX) has released OpenPhenom-S/16, a publicly available foundation model in Google Cloud's Vertex AI Model Garden. The model, trained on over three million microscopy images from public datasets, sets a new performance standard for microscopy data analysis, outperforming traditional methods like CellProfiler. The model enables automated classification of cellular structures and pattern detection without requiring additional tuning. Alongside the model, Recursion is releasing the RxRx3-core dataset, which includes labeled images of 735 genetic knockouts and 1,674 small-molecule perturbations, designed to advance research in drug mechanism mapping.
Recursion (RXRX) reported Q3 2024 financial results with revenue of $26.1 million, up from $10.5 million in Q3 2023. The company achieved multiple clinical milestones, including positive Phase 2 CCM trial data and FDA clearance for a Phase 1/2 trial in biomarker-enriched tumors. Roche-Genentech optioned their first neuroscience phenomap for $30 million. The company expanded its collaboration with Google Cloud for drug discovery platform support. Q3 net loss was $95.8 million with cash position of $427.6 million. The pending business combination with Exscientia is expected to close on November 20, 2024.
Recursion (NASDAQ: RXRX) announced it will release its Q3 2024 business updates and financial results on November 6, 2024, after market close. The company will not hold its regular earnings call for Q3. Instead, Recursion plans to host an update call on November 20, 2024, following the expected completion of its proposed business combination with Exscientia. The call will be streamed live on Recursion's social media platforms, including X (formerly Twitter), LinkedIn, and YouTube, with opportunities for Q&A.
Recursion (NASDAQ: RXRX) has dosed the first patient in its Phase 2 clinical trial of REC-3964, an oral, non-antibiotic small molecule designed for recurrent Clostridioides difficile (C. diff) infection. The novel treatment selectively inhibits the glucosyltransferase activity of toxin B produced by C. diff, aiming to prevent recurrence while sparing the gut microbiome. C. diff infections cause significant morbidity and mortality, with up to 175,000 recurrent cases annually in the U.S. and high recurrence rates post-antibiotic treatment. Preclinical studies showed REC-3964's superiority over bezlotoxumab, and Phase 1 trials demonstrated its safety and tolerability. The Phase 2 ALDER trial will enroll around 80 participants across the U.S. and Europe to assess safety, tolerability, pharmacokinetics, and efficacy.
Recursion (NASDAQ: RXRX) has received FDA clearance for an Investigational New Drug (IND) application for REC-1245, a potential first-in-class RBM39 degrader targeting biomarker-enriched solid tumors and lymphoma. This program, developed using Recursion's AI-enabled active learning modules, progressed from target identification to IND-enabling studies in under 18 months.
The company plans to initiate a Phase 1/2 clinical trial in Q4 2024, evaluating REC-1245 in a biomarker-enriched patient population. Recursion identified RBM39's novel regulatory role associated with CDK12 using its maps of biology. The company estimates the initially addressable population for this potential therapeutic to be over 100,000 patients in the US and EU5.
Preclinical data suggest that RBM39 degradation induces splicing defects, downregulating DNA Damage Response networks and cell cycle checkpoints. The upcoming clinical trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential monotherapy efficacy of REC-1245.
Recursion (NASDAQ: RXRX) announced positive top-line results from its SYCAMORE trial, a Phase 2 study of REC-994 for symptomatic Cerebral Cavernous Malformation (CCM). The trial met its primary endpoint of safety and tolerability, with similar profiles across placebo and both 200mg and 400mg dosage arms. Encouraging trends in MRI-based secondary efficacy endpoints were observed, particularly at the highest dose (400mg), showing reduced lesion volume and hemosiderin ring size compared to placebo.
The company plans to advance REC-994's development for potential CCM treatment in subsequent studies. A meeting with the FDA is anticipated to discuss plans for an additional clinical study. Recursion aims to present the data at a future medical conference and submit it for peer-reviewed publication.
Recursion (Nasdaq: RXRX) issued a correction to its earlier press release regarding its second quarter 2024 financial results. The company clarified that its earnings call took place earlier in the morning on Aug 8, 2024 at 8:30 am Eastern Time / 6:30 am Mountain Time, rather than being scheduled for later in the afternoon as previously stated. The live stream of the call was broadcast from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts, providing opportunities for questions. No other changes were made to the original release.
Recursion (RXRX) and Exscientia (EXAI) have announced a definitive agreement to merge, creating a global technology-enabled drug discovery leader. The combination aims to leverage Recursion's biology exploration and Exscientia's precision chemistry design capabilities. Key highlights include:
- Expected annual synergies of approximately $100 million
- Combined pipeline with 10 clinical readouts expected in the next 18 months
- Potential for $200 million in milestone payments over 24 months
- Well-capitalized with $850 million in cash and equivalents
- Exscientia shareholders to receive 0.7729 shares of Recursion for each share owned
The merger is expected to close by early 2025, subject to shareholder and regulatory approvals. The combined company will retain the Recursion name and be headquartered in Salt Lake City, Utah.